HZB Researcher on the Board of Directors of the Materials Research Society
Catherine Dubourdieu is head of the IFOX Institute at HZB and was elected now into the board of directors of the MRS.
In September 2019, Prof. Dr. Catherine Dubourdieu was elected into the Board of Directors of the Materials Research Society (MRS). The MRS is one of the largest scientific associations and has almost 14000 members from various areas of the natural sciences and engineering.
Catherine Dubourdieu heads the HZB-Institute IFOX (Functional Oxides for Energy Efficient Information Technology) and holds a professorship at the Freie Universität Berlin. She investigates the growth and properties of functional oxides and semiconductor materials with the aim of developing energy-efficient devices for information technology, that can be integrated on silicon chips. Over the past 15 years, the physicist has also established numerous collaborations with industry and holds 10 patents. She has already published over 140 articles in peer-review journals and has an excellent international network.
In the Materials Research Society Catherine Dubourdieu has been active for over 20 years, also in responsible functions. As of 2020, Catherine Dubourdieu will be a member of the MRS Board of Directors to support the global materials research community and provide a framework for the various disciplines to collaborate.
The MRS's mission is to advance international interdisciplinary materials research and technology for the benefit of the human society. It was founded in 1973 and today has around 14000 members from various areas of the natural sciences and engineering. The governance of the Society is the responsibility of the Board of Directors, composed of 6 officers and 18 directors, 15 of whom are elected by the membership. One third of the Board is renewed each year. Catherine Dubourdieu will serve in this position over the next three years.
- Fascinating archaeological find becomes a source of knowledgeThe Bavarian State Office for the Preservation of Historical Monuments (BLfD) has sent a rare artefact from the Middle Bronze Age to Berlin for examination using cutting-edge, non-destructive methods. It is a 3,400-year-old bronze sword, unearthed during archaeological excavations in Nördlingen, Swabia, in 2023. Experts have been able to determine how the hilt and blade are connected, as well as how the rare and well-preserved decorations on the pommel were made. This has provided valuable insight into the craft techniques employed in southern Germany during the Bronze Age. The BLfD used 3D computed tomography and X-ray diffraction to analyse internal stresses at the Helmholtz-Zentrum Berlin (HZB), as well as X-ray fluorescence spectroscopy at a BESSY II beamline supervised by the Bundesanstalt für Materialforschung und -prüfung (BAM).
- MXene for energy storage: More versatile than expectedMXene materials are promising candidates for a new energy storage technology. However, the processes by which the charge storage takes place were not yet fully understood. A team at HZB has examined, for the first time, individual MXene flakes to explore these processes in detail. Using the in situ Scanning transmission X-ray microscope 'MYSTIIC' at BESSY II, the scientists mapped the chemical states of Titanium atoms on the MXene flake surfaces. The results revealed two distinct redox reactions, depending on the electrolyte. This lays the groundwork for understanding charge transfer processes at the nanoscale and provides a basis for future research aimed at optimising pseudocapacitive energy storage devices.
- Bernd Rech elected to the BR50 Board of DirectorsThe Scientific Director at Helmholt-Zentrum Berlin is the new face behind the "Natural Sciences" unit at Berlin Research 50 (BR50). Following the election in December 2025, the constituent meeting of the new BR50 Board of Directors took place on 22 January 2026.
Its members are Michael Hintermüller (Weierstrass Institute, WIAS), Noa K. Ha (German Centre for Integration and Migration Research, DeZIM), Volker Haucke (Leibniz Research Institute for Molecular Pharmacology, FMP), Uta Bielfeldt (German Rheumatism Research Centre Berlin, DRFZ) and Bernd Rech (HZB).